Amarantus Bioscience Holdings, Inc. – "Commercialization On-Track for 2014: Updating LymPro Test(R) Progress"

Publishing & Media

Share Tweet

Amarantus Bioscience Holdings, Inc. – "Commercialization On-Track for 2014: Updating LymPro Test(R) Progress"

SAN FRANCISCO, CA / March 31, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Commissiong outlines Amarantus' recent achievement of key milestones that the company believes will add significant value in the commercialization and development of the LymPro test (R) for Alzheimer's. "As we prepare for LymPro's commercialization in the second half of 2014, we believe it is critical to properly position LymPro within the scientific community, the investment community and the general population as THE commercially-validated blood test as we prepare for product launch," states Mr. Commissiong. Read the full blog post from Mr. Gerald Commissiong on (

About Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.


SOURCE: Amarantus Bioscience Holdings, Inc.